Dranitsaris, George; Elia-Pacitti, Julia; Cottrell, Wayne - In: PharmacoEconomics 22 (2004) 6, pp. 375-387
Background: Docetaxel is an equally active alternative to paclitaxel in advanced ovarian cancer but has a different … for docetaxel as an alternative to paclitaxel in patients with advanced ovarian cancer. Design and setting: A cost … ovarian cancer was provided including its current management, and differences in adverse effects between docetaxel and …